3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase NA
1
Status
Completed
3
Enrolling by invitation
1
Sponsor Class
INDUSTRY
2
OTHER_GOV
1
Study Type
Interventional
3
Sponsor
Conditions
Arthritis, Rheumatoid
13
Spondylitis, Ankylosing
4
Psoriasis
4
Colitis, Ulcerative
3
Uveal Melanoma
1
Spondylarthritis
1
Recurrence
1
Plaque Psoriasis
1
Osteoarthritis
1
Nephrotic Syndrome
1
Nephrosis, Lipoid
1
Mucopolysaccharidosis VI
1
Mucopolysaccharidosis II
1
Mucopolysaccharidosis I
1
Mucopolysaccharidoses
1
Melanoma
1
Macular dystrophy, corneal type 1
1
Kidney Diseases
1
Joint Diseases
1
Inflammatory Bowel Diseases
1
Inflammation
1
Hidradenitis Suppurativa
1
Healthy
1
Glomerulosclerosis, Focal Segmental
1
Dupuytren Contracture
1
Crohn Disease
1
Arthritis, Psoriatic
1
Arthritis
1
Acne Vulgaris
1
Abscess
1
Interventions
etrolizumab
5
Infliximab
4
Adalimumab
3
golimumab
2
CT-P13
2
peficitinib
1
Sutures
1
Surgical Instruments
1
Ringer's Lactate
1
Proctectomy
1
Pneumococcal Vaccines
1
Papillomavirus Vaccines
1
Methylprednisolone
1
Mesalamine
1
Lysine Acetyltransferase 5
1
Laparoscopy
1
Injections
1
Hydroxyethyl Starch Derivatives
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Eicosapentaenoic Acid
1
CVD protocol
1
ABX464
1
2-(3',4'-dihydroxyphenyl-1-azo)benzimidazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Colitis, Ulcerative
×
Adalimumab
×
Clear all
NCT03011268
2025-05-31
BIOSTOP
Helse Møre og Romsdal HF
Phase NA
Completed
174 enrolled
NCT02163759
2021-07-23
HIBISCUS I
Hoffmann-La Roche
Phase 3
Completed
358 enrolled
42 charts
NCT02171429
2021-07-23
HIBISCUS II
Hoffmann-La Roche
Phase 3
Completed
358 enrolled
38 charts